New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery

Core Insights - Optinose announced the peer-reviewed publication of a study on the efficacy of EDS-FLU in treating chronic rhinosinusitis (CRS) in patients with or without prior sinus surgery [1][4] Company Overview - Optinose is a specialty pharmaceutical company focused on patients treated by ear, nose, and throat (ENT) and allergy specialists [5] - The company’s product, XHANCE, is a drug-device combination approved for treating both chronic rhinosinusitis without nasal polyps and with nasal polyps in patients aged 18 and older [6] Product Efficacy - The study published in the International Forum of Allergy & Rhinology highlighted that the Exhalation Delivery System™ (EDS) allows for effective medication delivery to sinus cavities, which is crucial for treating CRS [2][3] - Results from the ReOpen1 and ReOpen2 trials indicated that XHANCE significantly improved symptoms, sinus opacification, and quality of life in CRS patients, regardless of prior sinus surgery [4] Clinical Trials - The ReOpen1 and ReOpen2 trials were 24-week randomized controlled studies comparing XHANCE to a placebo in CRS patients [3] - The findings suggest that prior sinus surgery is not a prerequisite for patients to benefit from XHANCE treatment [4]